Supplementary Table 10: Interstudy analysis of individual systematic adverse events reported in vaccine group (excluding control group) of coronavirus vaccine studies. Data represent % of patients in experimental group reporting any grade of symptomatic adverse event.

Study (% Patients)	Headache	Myalgia	Fatigue	Arthralgia	Fever	Nausea	Chills	Diarrhoea	Appetite impairment	Vomiting	Abdominal Pain	Hyper-sensitivity	Itch	Mucosal abnormality	Feverishness	Cough
Zhu, AdH5 (Phase 1) (n=108)	39	17	44	8	46	6	-	11	16	2	-	-	3	1	-	6
Zhu, AdH5 (Phase 2) Low Dose (n=129)	28	18	34	10	16	5	-	8	5	1	-	0	3	2	-	2
Zhu, AdH5 (Phase 2) High Dose (n=253)	29	15	42	13	32	8	-	8	11	2	-	0	2	1	-	5
Logunov, AdH26/5-Vac (n=38)	52.6	26.3	44.7	26.3	81.6	-	-	10.5	7.8	-	-	-	-	-	-	5.3
Logunov, AdH26/5-Lyo (n=38)	31.6	23.7	10.5	23.7	23.7	-	-	0	0	-	-	-	-	-	-	0
Sadoff, Ad26.COV2.S (n=805)	43.5	37	41.1	-	15.8	15.5	-	-	-	-	-	-	-	-	-	-
Ramasamy, ChAdOx Prime (n=128)	36.6	27.3	41.5	13.8	5.7	7.3	13.0	-	-	-	-	-	-	-	16.9	-
Ramasamy, ChAdOx Boost (n=128)	19.6	18.1	23.5	5.0	0.0	6.2	4.3	-	-	-	-	-	-	-	7.3	-
Folegatti, ChAdOx (Phase 1/2) (n=543)	67.2	59.1	70.0	30.6	17.7	26.3	52.9	-	-	-	-	-	-	-	49.7	-
Baden, mRNA-1273 Prime (n=15,210)	32.7	22.7	37.2	16.6	0.8	8.3	8.3	-	-	-	-	-	-	-	-	-
Baden, mRNA-1273 Boost (n=15,210)	58.6	58	65.3	42.8	15.5	19	44.2	-	-	-	-	-	-	-	-	-
Jackson, mRNA-1273 Prime (n=45)	31.0	13.7	29.3	6.7	0.0	5.0	6.7	-	-	-	-	-	-	-	-	-
Jackson, mRNA-1273 Boost (n=45)	60.7	56.3	62.7	27.7	32.0	24.0	59.3	-	-	-	-	-	-	-	-	-
Anderson, mRNA-1273 Prime (n=40)	12.5	20	25	10	0	0	-	-	-	-	-	-	-	-	-	-
Anderson, mRNA-1273 Boost (n=40)	40	50	50	12.5	7.5	17.5	-	-	-	-	-	-	-	-	-	-

Chu, mRNA-1273 Prime (n=600)	25.5	12.5	24.5	9	0.0025	4.5	6	-	-	-	-	-	-	-	-	-
Chu, mRNA-1273 Boost (n=600)	51	47.5	59	37	9.5	17	32	-	-	-	-	-	-	-	-	-
Polack, BNT162b2 Prime (n=21,720)	33.5	17.5	40.5	10	2.5	-	10	9.5	-	0.5	-	-	-	-	-	-
Polack, BNT162b2 Boost (n=21,720)	45.5	33	55	20.5	13.5	-	29	9	-	1.5	-	-	-	-	-	-
Mulligan, BNT162b1 Prime (n=36)	55	29.3	55.7	13.3	22.0	-	49.0	18.3	-	0	-	-	-	-	-	-
Mulligan, BNT162b1 Boost (n=24)	87.5	50	75	25	41.5	-	47.5	4	-	0	-	-	-	-	-	-
Walsh, BNT162b1 Prime (n=84)	46.4	28.5	45.8	16.6	6.8	-	20.7	10.6	-	0	-	-	-	-	-	-
Walsh, BNT162b1 Boost (n=72)	73.6	45.6	63.8	29.0	25.5	-	43.0	6.93	-	1.38	-	-	-	-	-	-
Walsh, BNT162b2 Prime (n=72)	24.9	13.9	29.2	4.1	2.8	-	8.3	2.8	-	1.38	-	-	-	-	-	-
Walsh, BNT162b2 Boost (n=72)	36.0	26.4	45.8	8.3	5.5	-	25.0	0	-	1.38	-	-	-	-	-	-
Che, inactivated SARS-COV-2 (n=600)	-	-	5.33	-	2.70	0.83	-	1.67	-	0	-	0.6	-	0.33	-	1.83
Wu, Coronavac I/II (n=421)	1.4	1.1	3.4	0.0	3.7	0.6	-	1.1	-	0.3	0.0	0.3	-	-	-	0.9
Ella, BBV152 Prime I (n=300)	2.7	1.0	2.0	-	1.7	1.7	-	-	-	-	-	-	-	-	-	-
Ella, BBV152 Boost I (n=300)	0.0	0.3	1.7	-	1.3	0.0	-	-	-	-	-	-	-	-	-	-
Ella, BBV152 II (n=380)	2.5	2	2.5	-	6	-	-	-	-	-	-	-	-	-	-	-
Xia, BBIPB Phase I (n=144)	2	0	2	0.5	3.5	-	-	1.5	0.5	1	-	-	1	1	-	-
Xia, BBIPB Phase II (n=336)	1	<1	3	-	2	1	-	-	-	-	-	-	1	-	-	1
Zhang, CoronaVac (n=570)	2.1	2.1	5.9	-	3.3	1.3	2.1	-	1.0	0.3	-	0.5	-	-	-	0.96
Keech, NVX-CoV2373 Prime (n=102)	32.3	23.3	29.6	8.9	0.0	9.9	-	-	-	-	-	-	-	-	-	-
Keech, NVX-CoV2373 Boost (n=76)	44.8	34.4	32.4	15.8	1.7	11.4	-	-	-	-	-	-	-	-	-	-
Tebas, INO-4800 Prime (n=40)	0	0	0	0	0	2.5	0	-	-	-	-	-	-	-	-	-
Tebas, INO-4800 Boost (n=40)	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-

Richmond, SCB-2019 Prime (n=121)	16.7	10.8	10.8	-	0.0	1.7	-	2.5	-	2.5	-	-	-	-	-	-
Richmond, SCB-2019 Boost (n=121)	15.0	13.3	16.7	-	5.0	5.0	-	0.0	-	0.8	-	-	-	-	-	-
Koch, MERS MVA (n=26)	62	19	62	15	8	8	4	3	-	-	19	-	-	-	-	-
Martin, SARS DNA (n=10)	10	30	-	-	1	0	1	-	-	-	-	-	-	-	-	-
Lin, SARS Inactivated (n=24)	4.2	4.2	4.2	-	4.2	-	-	15.5	-	-	12.5	-	-	-	-	-
Modjarrad, GLS-5300 MERS (n=75)	30.7	14.7	18.7	5.3	-	12	-	-	-	-	-	-	-	-	-	-
Folegatti, ChAdOx 1 MERS (n=24)	66.7	54.2	66.7	33.3	20.8	33.3	-	-	-	-	-	-	-	-	50	-